Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Combinatory therapeutic approaches of different targeted therapies in acute myeloid leukaemia are currently under preclinical/early clinical investigation. To enhance anti-tumour effects, we combined the tyrosine kinase inhibitor (TKI) midostaurin and T-cell mediated immunotherapy directed against CD33. Clinically relevant concentrations of midostaurin abrogated T-cell mediated cytotoxicity both after activation with bispecific antibodies and chimeric antigen receptor T cells. This information is of relevance for clinicians exploring T-cell mediated immunotherapy in early clinical trials. Given the profound inhibition of T-cell functionality and anti-tumour activity, we recommend specific FLT3 TKIs for further clinical testing of combinatory approaches with T-cell based immunotherapy.
Details
Original language | English |
---|---|
Pages (from-to) | 735-740 |
Number of pages | 6 |
Journal | British journal of haematology |
Volume | 186 |
Issue number | 5 |
Publication status | Published - 2019 |
Peer-reviewed | Yes |
External IDs
PubMed | 31119728 |
---|
Keywords
ASJC Scopus subject areas
Keywords
- acute myeloid leukaemia, combinatory therapy, midostaurin, T-cell based immunotherapy